Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Change in Account Payables (2017 - 2025)

Cue Biopharma's Change in Account Payables history spans 9 years, with the latest figure at -$1.3 million for Q3 2025.

  • For Q3 2025, Change in Account Payables fell 149.86% year-over-year to -$1.3 million; the TTM value through Sep 2025 reached -$4.1 million, down 203.33%, while the annual FY2024 figure was -$678000.0, 188.05% down from the prior year.
  • Change in Account Payables for Q3 2025 was -$1.3 million at Cue Biopharma, down from -$157000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.6 million in Q3 2024 and bottomed at -$3.6 million in Q4 2024.
  • The 5-year median for Change in Account Payables is $124000.0 (2023), against an average of $11547.3.
  • The largest annual shift saw Change in Account Payables plummeted 2330.77% in 2023 before it soared 1970.16% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at $120398.0 in 2021, then soared by 422.43% to $629000.0 in 2022, then soared by 62.32% to $1.0 million in 2023, then crashed by 457.49% to -$3.6 million in 2024, then surged by 64.93% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Change in Account Payables are -$1.3 million (Q3 2025), -$157000.0 (Q2 2025), and $961000.0 (Q1 2025).